Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines acknowledges that excess weight is a chronic disease that can be managed with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant barriers to broad access to the injections that can help people shift considerable weight, explains the agency.
Weight-Loss Drug Scarcity
Even under the present most optimistic scenario, the supply of these medications could only cover about 100 million people – under 10% of those who need them, as stated by the health organization.
The advice urges countries and companies to expand availability, by measures like patent sharing.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Jabs Function
These medications replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so people consume fewer calories.
People commonly see weight reduction in the initial weeks of commencing the regular doses.
Research indicates people may regain a significant portion within a year of stopping the treatment, when their normal food cravings come back.
To be above a healthy weight raises your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight concerns individuals in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.
